Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JADE101 · 3 trials · 3 indications
The proportion of participants who experience one or more adverse events that begin or worsen after the first dose of study drug
Incidence of treatment-emergent adverse events
Maximum observed serum concentration
Time to reach Cmax
The area under the concentration-time curve from time zero to the time of the last observed quantifiable (non-zero) concentration
Apparent first-order terminal elimination half-life
Incidence of treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| JADE101 | EXPERIMENTAL | Subcutaneous (SC) injection of JADE101 |
| JADE101 Groups 1 and 2 | EXPERIMENTAL | Subcutaneous (SC) injection of JADE101 |
| JADE101 Groups 3 and 4 | EXPERIMENTAL | Subcutaneous (SC) injection of JADE101 |
| Placebo | PLACEBO_COMPARATOR | Subcutaneous (SC) injection of placebo |
| Name | Type | Description |
|---|---|---|
| JADE101 | DRUG | JADE101 is supplied as sterile solution to be administered by SC injection |
| Placebo | DRUG | Placebo solution to be administered at a matching volume by SC injection. |
Inclusion Criteria: 1. Male or female participants 18-60 years of age, inclusive, and of local legal consenting age at the time of signing the informed consent 2. eGFR ≥ 30 mL/min/1.73 m2 3. Biopsy-confirmed primary IgAN 4. Receiving stable and maximally tolerated doses of either ACEi or ARB as per...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 10 | PHASE3 | BION-1301 |
| Vera Therapeutics, Inc. Class A | VERA | 4 | PHASE3 | Atacicept |
| Travere Therapeutics, Inc. | TVTX | 2 | PHASE3 | sparsentan, irbesartan, Dapagliflozin |
| Biogen Inc. | BIIB | 1 | PHASE3 | Felzartamab |
| AstraZeneca PLC | AZN | 2 | PHASE3 | Ravulizumab |
| Vertex Pharmaceuticals Incorporated | VRTX | 2 | PHASE3 | Povetacicept |
| Biohaven Ltd. | BHVN | 1 | PHASE1 | BHV-1400 |
| Jade Biosciences, Inc. | JBIO | 1 | PHASE2 | JADE101 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-097 |